Stockscreener 앱 받기
1.68
1.20%
0.02
시간 외 거래:
1.69
0.01
+0.60%
전일 마감가:
$1.66
열려 있는:
$1.68
하루 거래량:
3.56M
Relative Volume:
0.47
시가총액:
$568.71M
수익:
$4.41M
순이익/손실:
$-67.85M
주가수익비율:
-7.4402
EPS:
-0.2258
순현금흐름:
$-57.15M
1주 성능:
+0.00%
1개월 성능:
-10.16%
6개월 성능:
+12.00%
1년 성능:
+130.80%
1일 변동 폭
$1.63
$1.70
1주일 범위
$1.58
$1.765
52주 변동 폭
$0.64
$2.725
오큐젠 Stock (OCGN) Company Profile
명칭
Ocugen Inc
전화
484-328-4701
주소
11 GREAT VALLEY PARKWAY, MALVERN, PA
Compare OCGN vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
1.68 | 561.94M | 4.41M | -67.85M | -57.15M | -0.2258 |
VRTX
Vertex Pharmaceuticals Inc
|
423.24 | 109.41B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
686.36 | 76.72B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
776.02 | 48.20B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.19 | 40.31B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
290.80 | 33.13B | 5.36B | 287.73M | 924.18M | 2.5229 |
오큐젠 Stock (OCGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-17 | 개시 | Canaccord Genuity | Buy |
| 2026-03-11 | 개시 | Oppenheimer | Outperform |
| 2024-10-15 | 개시 | Maxim Group | Buy |
| 2023-03-01 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2022-08-23 | 개시 | Mizuho | Buy |
| 2022-06-15 | 재개 | ROTH Capital | Buy |
| 2022-06-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-07-26 | 개시 | Noble Capital Markets | Outperform |
| 2021-06-11 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2021-05-07 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-09 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2021-02-04 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
모두보기
오큐젠 주식(OCGN)의 최신 뉴스
OCGN stock tanks after gene therapy trial update — what did Ocugen announce? - MSN
Ocugen to Host Conference Call on Tuesday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2026 Financial Results - The Manila Times
Ocugen plans pre-market earnings release, webcast on May 5 - Stock Titan
Ocugen (OCGN) up 2.9% since last earnings report: Can it continue? - MSN
Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch
[ARS] Ocugen, Inc. SEC Filing - Stock Titan
Ocugen (NASDAQ: OCGN) 2026 proxy outlines pipeline gains and pay plans - Stock Titan
Ocugen Inc. stock rises Monday, outperforms market - MarketWatch
Ocugen (OCGN) price target increased by 11.11% to 10.20 - MSN
Ocugen prices $22.5M common stock offering at $1.50 per share - MSN
OCGN stock rallies on Wall Street optimism for clinical pipeline: Retail awaits new data - MSN
How The Ocugen (OCGN) Story Is Shifting With Gene Therapy Milestones And Valuation Debate - Yahoo Finance
Ocugen Stock Rises On Better-Than-Feared Q1 Loss: Retail Turns Bullish - MSN
OCGN Q1'26 Earnings: revenue estimate is 417.83K USD - TradingView
OCGN Technical Analysis | Trend, Signals & Chart Patterns | OCUGEN INC (NASDAQ:OCGN) - ChartMill
Ocugen Q4 2025 earnings preview - MSN
Ocugen taps Rita Johnson-Greene as CFO - MSN
Ocugen to Present at April 2026 Investor and Industry Conferences - Ocugen, Inc.
Ocugen, Inc. advances gene therapy platform as CEO and EVP present at global biotech events - Traders Union
Ocugen, Inc. Leaders to Present at Upcoming Biotechnology Conferences in Puerto Rico and Italy - Quiver Quantitative
Ocugen (OCGN) Valuation Check After Encouraging Phase 2 ArMaDa Results For OCU410 - Yahoo Finance
OCGN's Gene-Agnostic Strategy Could Reset Retinal Therapy - The Globe and Mail
Ocugen Inc. stock falls Wednesday, underperforms market - MarketWatch
OCGN Gene Therapy Pipeline: Key 2026-27 Catalysts Ahead - TradingView
Ocugen Stock Outlook: Valuation, Cash Runway and Dilution Risk - Yahoo Finance
OCGN Ocugen Inc. shares rise more than 3 percent even as Q4 2025 earnings narrowly fall short of analyst estimates. - Cổng thông tin điện tử tỉnh Tây Ninh
OCU410’s Phase 2 Gene‑Agnostic Results in Dry AMD Might Change The Case For Investing In Ocugen (OCGN) - Yahoo Finance
Ocugen Inc. stock falls Monday, underperforms market - MarketWatch
Reverse split 1:2–1:8; OCU400 Phase 3 topline expected Q1 2027 — Ocugen (OCGN) - Stock Titan
Ocugen (NASDAQ:OCGN) Shares Gap DownShould You Sell? - MarketBeat
Ocugen Inc stock (US67577C1053): Is its gene therapy pipeline strong enough to unlock biotech upside - AD HOC NEWS
OCGN Stock Holds Support As Traders Map Next Move - StocksToTrade
OCGN Stock Holds Range As Traders Weigh Heavy Losses - timothysykes.com
Ocugen's High-Wire Act: Balancing Clinical Promise Against a Cash Crunch - AD HOC NEWS
Ocugen Inc. (OCGN): One of the popular penny stocks on Robinhood - MSN
Ocugen Inc. stock rises Friday, outperforms market - MarketWatch
Ocugen (NASDAQ: OCGN) completes OCU400 Phase 3 enrollment; financing extends runway - Stock Titan
Ocugen's Triple-Threat Gene Therapy Pipeline Faces a Cash Countdown - AD HOC NEWS
Ocugen, Inc. outlines mass-market gene therapy push with planned BLAs for blindness treatments - Traders Union
Ocugen Inc. stock falls Thursday, underperforms market - MarketWatch
Ocugen, Inc. (NASDAQ:OCGN) Short Interest Update - MarketBeat
Ocugen Inc. stock rises Wednesday, outperforms market - MarketWatch
Ocugen, Inc. reports 31 percent drop in GA lesion growth with OCU410 medium dose in phase 2 trial - Traders Union
[SCHEDULE 13G] Ocugen, Inc. Passive Investment Disclosure (>5%) - Stock Titan
오큐젠 (OCGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.39%
0.10%
자본화:
|
볼륨(24시간):